Methodology

All entries for: Sanegene Bio USA Inc.

February 23, 2026

Sanegene Bio USA Inc.

Orphan Drug Designation

treatment of immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN )

Disease Area: Rare Disease
Source
October 16, 2025

Sanegene Bio USA Inc.

Orphan Drug Designation

FDA orphan drug designation: treatment of complement 3 glomerulopathy

Disease Area: Rare Diseases
Source
Source
Scroll to Top